ELS - VHD and Transcatheter Aortic Valve Replacement

Transcatheter Aortic Valve Replacement

ACCF Transcatheter Aortic Valve Replacement GUIDELINES App brought to you free of charge courtesy of Guideline Central. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/109740

Contents of this Issue

Navigation

Page 1 of 9

Key Points ����The most common cause of valvular aortic stenosis (AS) in adults is calcification of a normal tricuspid or congenital bicuspid valve. ����Calcific AS typically presents in older individuals (ie, >75 years) in contrast to bicuspid AS, which presents a decade or more earlier. ����Stroke, the greatest risk accompanying aortic valve replacement (AVR), can be kept under 2% even in octogenerians by careful patient selection. ����Transcatheter aortic valve replacement (TAVR) offers new and potentially transformational technology for patients with severe aortic valvular stenosis who are either extremely high-risk candidates or inoperable for surgical AVR or who are inoperable by virtue of associated comorbidities. ����An estimated 40,000 patients have received TAVR worldwide. Aortic Stenosis ������ Predicted survial ��� <12 months ������ Prohibitive TAVR risk ������ Severe ������ Symptomatic Medical treatment including the potential for balloon valvuloplasty ������ Tricuspid valve ������ Prohibitive surgical risk OR High surgical risk ������ Severe ������ Hypotensive response to exercise ������ Moderate ������ Symptomatic ������ Need for related CV Surgery ������ Critical Aortic Stenosis TAVR AVR

Articles in this issue

Archives of this issue

view archives of ELS - VHD and Transcatheter Aortic Valve Replacement - Transcatheter Aortic Valve Replacement